4-iodo-6-phenylpyrimidine profile

4-iodo-6-phenylpyrimidine: acts on macrophage migration inhibitory factor; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

4-iodo-6-phenylpyrimidine : A member of the class of pyrimidines carrying iodo and phenyl substituents at positions 4 and 6 respectively. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

ID Source	ID
PubMed CID	817368
CHEMBL ID	497802
CHEBI ID	91213
SCHEMBL ID	244108
MeSH ID	M0525862

Synonym
AC-907/25004997
4-iodo-6-phenylpyrimidine
bdbm50265608
CHEMBL497802 ,
AKOS005266491
S2643
BRD-K25690923-001-01-6
SCHEMBL244108
CHEBI:91213
41270-96-6
4-ipp
4-ipp, >=97% (hplc)
Q27163132
HMS3677L22
CS-0032891
HY-110063
BS-16773
HMS3413L22
mfcd00234609
D80476
4-ipp (4-iodo-6-phenylpyrimidine)
4-iodo-6-phenyl-pyrimidine
SB60581
PD021682
mif antagonist iii

Role	Description
macrophage migration inhibitory factor inhibitor	Any inhibitor of macrophage migration inhibitory factor (MIF).
antineoplastic agent	A substance that inhibits or prevents the proliferation of neoplasms.
apoptosis inducer	Any substance that induces the process of apoptosis (programmed cell death) in multi-celled organisms.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
pyrimidines	Any compound having a pyrimidine as part of its structure.
biaryl	An organic aromatic compound whose structure contains two aromatic rings or ring systems, joined to each other by a single bond.
organoiodine compound	An organoiodine compound is a compound containing at least one carbon-iodine bond.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Macrophage migration inhibitory factor	Homo sapiens (human)	IC50 (µMol)	4.5000	0.0380	3.0910	9.8000	AID410821
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
prostaglandin biosynthetic process	Macrophage migration inhibitory factor	Homo sapiens (human)
positive regulation of cytokine production	Macrophage migration inhibitory factor	Homo sapiens (human)
negative regulation of mature B cell apoptotic process	Macrophage migration inhibitory factor	Homo sapiens (human)
inflammatory response	Macrophage migration inhibitory factor	Homo sapiens (human)
cell surface receptor signaling pathway	Macrophage migration inhibitory factor	Homo sapiens (human)
positive regulation of cell population proliferation	Macrophage migration inhibitory factor	Homo sapiens (human)
negative regulation of gene expression	Macrophage migration inhibitory factor	Homo sapiens (human)
positive regulation of protein kinase A signaling	Macrophage migration inhibitory factor	Homo sapiens (human)
negative regulation of macrophage chemotaxis	Macrophage migration inhibitory factor	Homo sapiens (human)
carboxylic acid metabolic process	Macrophage migration inhibitory factor	Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator	Macrophage migration inhibitory factor	Homo sapiens (human)
negative regulation of cell migration	Macrophage migration inhibitory factor	Homo sapiens (human)
positive regulation of B cell proliferation	Macrophage migration inhibitory factor	Homo sapiens (human)
positive regulation of lipopolysaccharide-mediated signaling pathway	Macrophage migration inhibitory factor	Homo sapiens (human)
positive regulation of tumor necrosis factor production	Macrophage migration inhibitory factor	Homo sapiens (human)
negative regulation of myeloid cell apoptotic process	Macrophage migration inhibitory factor	Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylation	Macrophage migration inhibitory factor	Homo sapiens (human)
positive regulation of phosphorylation	Macrophage migration inhibitory factor	Homo sapiens (human)
regulation of macrophage activation	Macrophage migration inhibitory factor	Homo sapiens (human)
negative regulation of apoptotic process	Macrophage migration inhibitory factor	Homo sapiens (human)
negative regulation of DNA damage response, signal transduction by p53 class mediator	Macrophage migration inhibitory factor	Homo sapiens (human)
innate immune response	Macrophage migration inhibitory factor	Homo sapiens (human)
positive regulation of fibroblast proliferation	Macrophage migration inhibitory factor	Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylation	Macrophage migration inhibitory factor	Homo sapiens (human)
positive chemotaxis	Macrophage migration inhibitory factor	Homo sapiens (human)
negative regulation of protein metabolic process	Macrophage migration inhibitory factor	Homo sapiens (human)
positive regulation of prostaglandin secretion involved in immune response	Macrophage migration inhibitory factor	Homo sapiens (human)
positive regulation of myeloid leukocyte cytokine production involved in immune response	Macrophage migration inhibitory factor	Homo sapiens (human)
protein homotrimerization	Macrophage migration inhibitory factor	Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascade	Macrophage migration inhibitory factor	Homo sapiens (human)
positive regulation of arachidonic acid secretion	Macrophage migration inhibitory factor	Homo sapiens (human)
cellular senescence	Macrophage migration inhibitory factor	Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator	Macrophage migration inhibitory factor	Homo sapiens (human)
positive regulation of chemokine (C-X-C motif) ligand 2 production	Macrophage migration inhibitory factor	Homo sapiens (human)
negative regulation of cellular senescence	Macrophage migration inhibitory factor	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
protease binding	Macrophage migration inhibitory factor	Homo sapiens (human)
dopachrome isomerase activity	Macrophage migration inhibitory factor	Homo sapiens (human)
cytokine activity	Macrophage migration inhibitory factor	Homo sapiens (human)
cytokine receptor binding	Macrophage migration inhibitory factor	Homo sapiens (human)
protein binding	Macrophage migration inhibitory factor	Homo sapiens (human)
chemoattractant activity	Macrophage migration inhibitory factor	Homo sapiens (human)
identical protein binding	Macrophage migration inhibitory factor	Homo sapiens (human)
phenylpyruvate tautomerase activity	Macrophage migration inhibitory factor	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
extracellular region	Macrophage migration inhibitory factor	Homo sapiens (human)
extracellular space	Macrophage migration inhibitory factor	Homo sapiens (human)
nucleoplasm	Macrophage migration inhibitory factor	Homo sapiens (human)
cytoplasm	Macrophage migration inhibitory factor	Homo sapiens (human)
cytosol	Macrophage migration inhibitory factor	Homo sapiens (human)
plasma membrane	Macrophage migration inhibitory factor	Homo sapiens (human)
cell surface	Macrophage migration inhibitory factor	Homo sapiens (human)
vesicle	Macrophage migration inhibitory factor	Homo sapiens (human)
secretory granule lumen	Macrophage migration inhibitory factor	Homo sapiens (human)
extracellular exosome	Macrophage migration inhibitory factor	Homo sapiens (human)
ficolin-1-rich granule lumen	Macrophage migration inhibitory factor	Homo sapiens (human)
extracellular space	Macrophage migration inhibitory factor	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Assay ID	Title	Year	Journal	Article
AID410821	Inhibition of human recombinant MIF tautomerase	2009	Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2	Discovery of human macrophage migration inhibitory factor (MIF)-CD74 antagonists via virtual screening.
AID1901111	Inhibition of MIF2 (unknown origin)	2022	Journal of medicinal chemistry, 02-10, Volume: 65, Issue:3	Thieno[2,3-
AID516526	Inhibition of human recombinant biotinylated MIF/CD74 interaction at 30 uM by mass spectrometry analysis	2010	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 20, Issue:19	Optimization of N-benzyl-benzoxazol-2-ones as receptor antagonists of macrophage migration inhibitory factor (MIF).
AID410820	Inhibition of human MIF-CD74 binding	2009	Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2	Discovery of human macrophage migration inhibitory factor (MIF)-CD74 antagonists via virtual screening.
AID516525	Inhibition of human recombinant MIF tautomerase at 30 uM by mass spectrometry analysis	2010	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 20, Issue:19	Optimization of N-benzyl-benzoxazol-2-ones as receptor antagonists of macrophage migration inhibitory factor (MIF).
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	3 (15.79)	29.6817
2010's	12 (63.16)	24.3611
2020's	4 (21.05)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	19 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
4-hydroxyphenylpyruvic acid 4-hydroxyphenylpyruvic acid: RN given refers to parent cpd. 4-hydroxyphenylpyruvic acid : A 2-oxo monocarboxylic acid that is pyruvic acid in which one of the methyl hydrogens is substituted by a 4-hydroxyphenyl group.	2.05	1	2-oxo monocarboxylic acid; phenols	human metabolite
metformin Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289). metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.	3.06	1	guanidines	environmental contaminant; geroprotector; hypoglycemic agent; xenobiotic
isoxazoles Isoxazoles: Azoles with an OXYGEN and a NITROGEN next to each other at the 1,2 positions, in contrast to OXAZOLES that have nitrogens at the 1,3 positions.. isoxazole : A monocyclic heteroarene with a structure consisting of a 5-membered ring containing three carbon atoms and an oxygen and nitrogen atom adjacent to each other. It is the parent of the class of isoxazoles.. isoxazoles : Oxazoles in which the N and O atoms are adjacent.	2.04	1	isoxazoles; mancude organic heteromonocyclic parent; monocyclic heteroarene
bortezomib [no description available]	2.13	1	amino acid amide; L-phenylalanine derivative; pyrazines	antineoplastic agent; antiprotozoal drug; protease inhibitor; proteasome inhibitor
trichostatin a trichostatin A: chelates zinc ion in the active site of histone deacetylases, resulting in preventing histone unpacking so DNA is less available for transcription; do not confuse with TRICHOSANTHIN which is a protein; found in STREPTOMYCES	2.07	1	antibiotic antifungal agent; hydroxamic acid; trichostatin	bacterial metabolite; EC 3.5.1.98 (histone deacetylase) inhibitor; geroprotector
melphalan Melphalan: An alkylating nitrogen mustard that is used as an antineoplastic in the form of the levo isomer - MELPHALAN, the racemic mixture - MERPHALAN, and the dextro isomer - MEDPHALAN; toxic to bone marrow, but little vesicant action; potential carcinogen.. melphalan : A phenylalanine derivative comprising L-phenylalanine having [bis(2-chloroethyl)amino group at the 4-position on the phenyl ring.	2.13	1	L-phenylalanine derivative; nitrogen mustard; non-proteinogenic L-alpha-amino acid; organochlorine compound	alkylating agent; antineoplastic agent; carcinogenic agent; drug allergen; immunosuppressive agent
dinoprostone prostaglandin E2 : Prostaglandin F2alpha in which the hydroxy group at position 9 has been oxidised to the corresponding ketone. Prostaglandin E2 is the most common and most biologically potent of mammalian prostaglandins.	2.31	1	prostaglandins E	human metabolite; mouse metabolite; oxytocic
3',4',7-trihydroxyisoflavone 3',4',7-trihydroxyisoflavone: from Streptomyces sp OH-1049; structure given in first source. 3',4',7-trihydroxyisoflavone : A 7-hydroxyisoflavone that is daidzein substituted by a hydroxy group at position 3'.	2.05	1	7-hydroxyisoflavones	antineoplastic agent; EC 1.3.1.22 [3-oxo-5alpha-steroid 4-dehydrogenase (NADP(+))] inhibitor; metabolite

Condition	Relationship Strength	Studies
Carcinoma, Non-Small Cell Lung [description not available]	2.41	1
Cancer of Lung [description not available]	2.52	2
Carcinoma, Non-Small-Cell Lung A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.	2.41	1
Lung Neoplasms Tumors or cancer of the LUNG.	2.52	2
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	3.26	5
Osteogenic Sarcoma [description not available]	2.41	1
Osteosarcoma A sarcoma originating in bone-forming cells, affecting the ends of long bones. It is the most common and most malignant of sarcomas of the bones, and occurs chiefly among 10- to 25-year-old youths. (From Stedman, 25th ed)	2.41	1
Rheumatoid Arthritis [description not available]	7.6	1
Innate Inflammatory Response [description not available]	2.6	1
Arthritis, Rheumatoid A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated.	2.6	1
Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.	7.6	1
Injuries, Spinal Cord [description not available]	2.91	3
Spinal Cord Injuries Penetrating and non-penetrating injuries to the spinal cord resulting from traumatic external forces (e.g., WOUNDS, GUNSHOT; WHIPLASH INJURIES; etc.).	2.91	3
Carcinoma, Epidermoid [description not available]	2.52	2
Angiogenesis, Pathologic [description not available]	2.17	1
Carcinoma, Squamous Cell A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)	2.52	2
Bone Loss, Osteoclastic [description not available]	2.21	1
Age-Related Osteoporosis [description not available]	2.21	1
Osteoporosis Reduction of bone mass without alteration in the composition of bone, leading to fractures. Primary osteoporosis can be of two major types: postmenopausal osteoporosis (OSTEOPOROSIS, POSTMENOPAUSAL) and age-related or senile osteoporosis.	2.21	1
Cancer of Head [description not available]	2.08	1
Invasiveness, Neoplasm [description not available]	2.08	1
Head and Neck Neoplasms Soft tissue tumors or cancer arising from the mucosal surfaces of the LIP; oral cavity; PHARYNX; LARYNX; and cervical esophagus. Other sites included are the NOSE and PARANASAL SINUSES; SALIVARY GLANDS; THYROID GLAND and PARATHYROID GLANDS; and MELANOMA and non-melanoma skin cancers of the head and neck. (from Holland et al., Cancer Medicine, 4th ed, p1651)	2.08	1
Kahler Disease [description not available]	2.53	2
Multiple Myeloma A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY.	2.53	2
Cancer of Colon [description not available]	3.06	1
Peritoneal Carcinomatosis [description not available]	3.06	1
Colonic Neoplasms Tumors or cancer of the COLON.	3.06	1
Peritoneal Neoplasms Tumors or cancer of the PERITONEUM.	3.06	1
Adenocarcinoma, Basal Cell [description not available]	2.04	1
Adenocarcinoma A malignant epithelial tumor with a glandular organization.	2.04	1
Infections, Pseudomonas [description not available]	2.05	1
Keratitis Inflammation of the cornea.	2.05	1
Pseudomonas Infections Infections with bacteria of the genus PSEUDOMONAS.	2.05	1

4-iodo-6-phenylpyrimidine

Description

Cross-References

Synonyms (25)

Roles (3)

Drug Classes (3)

Protein Targets (1)

Inhibition Measurements

Biological Processes (35)

Molecular Functions (8)

Ceullar Components (11)

Bioassays (5)

Research

Studies (19)

Market Indicators

Research Demand Index: 11.84

Study Types